Accessibility Menu
 
CERo Therapeutics logo

CERo Therapeutics

(OTC) CERO

Current Price$0.03
Market Cap$1.25M
Since IPO (2021)-100%
5 YearN/A
1 Year-100%
1 Month-3%

CERo Therapeutics Financials at a Glance

Market Cap

$1.25M

Revenue (TTM)

$0.00

Net Income (TTM)

$19.92M

EPS (TTM)

$-104.92

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.03

Volume

119,489

Open

$0.04

Previous Close

$0.03

Daily Range

$0.03 - $0.04

52-Week Range

$0.02 - $26.99

CERO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CERo Therapeutics

Industry

Biotechnology

Employees

8

CEO

Christopher B. Ehrlich, MBA

Headquarters

South San Francisco, CA 94080, US

CERO Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

3%

Return on Assets

-5%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.25M

Shares Outstanding

36.79M

Volume

119.49K

Avg. Volume

513.60K

Financials (TTM)

Gross Profit

$1.09M

Operating Income

$18.46M

EBITDA

$17.38M

Operating Cash Flow

$16.08M

Capital Expenditure

$0.00

Free Cash Flow

$16.08M

Cash & ST Invst.

$1.66M

Total Debt

$699.11K

CERo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$276.14K

-147.5%

Gross Margin

0.00%

N/A

Market Cap

$1.25M

N/A

Market Cap/Employee

$155.89K

N/A

Employees

8

N/A

Net Income

$4.54M

-464.9%

EBITDA

$4.15M

-368.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$963.27K

-45.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$699.11K

-20.2%

Return on Assets

-5.47%

N/A

Return on Invested Capital

3.39%

N/A

Free Cash Flow

$3.81M

-191.8%

Operating Cash Flow

$3.81M

-191.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTIXProtagenic Therapeutics, Inc.
$0.80-9.09%
XRTXXORTX Therapeutics Inc.
$2.78-2.80%
BCTXZBriaCell Therapeutics Corp. Warrant
$0.09+1.62%
GLMDGalmed Pharmaceuticals Ltd.
$0.57+0.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.70+0.01%
NIONio
$5.91-0.08%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$50.22-0.03%

Questions About CERO

What is the current price of CERo Therapeutics?

CERo Therapeutics is trading at $0.03 per share.

What is the 52-week range for CERo Therapeutics?

Over the past 52 weeks, CERo Therapeutics has traded between $0.02 and $26.99.

How much debt does CERo Therapeutics have?

As of the most recent reporting period, CERo Therapeutics reported total debt of $699,107.

How much cash does CERo Therapeutics have on hand?

CERo Therapeutics reported $1.66M in cash and cash equivalents in its most recent financial results.

What is CERo Therapeutics’s dividend yield?

CERo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.